original ) (raw )Neisseria meningitidis Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12-23 Months Following Meningococcal Vaccination
George Carlone
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2015
View PDFchevron_right
Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands
Guy Berbers
BMC Infectious Diseases, 2012
View PDFchevron_right
Evaluation of Meningococcal Serogroup C Bactericidal Antibodies after Primary Vaccination: A Multicentre Study, Italy
Massimo Fabiani
Vaccines
View PDFchevron_right
Young-adult carriers of Neisseria meningitidis in Puglia (Italy): Will the pattern of circulating meningococci change following the introduction of meningococcal serogroup C conjugate vaccines?
Domenico Martinelli
Human Vaccines, 2010
View PDFchevron_right
Investigation of serum bactericidal activity in childhood and adolescence 3–6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine
Anastasia Barbouni , Georgina Tzanakaki
Vaccine, 2009
View PDFchevron_right
Age-dependent Neisseria meningitidis serogroup C class-specific antibody concentrations and bactericidal titers in sera from young children from Montana immunized with a licensed polysaccharide vaccine
George Carlone
Infection and immunity, 1998
View PDFchevron_right
Meningococcal serogroup C-specific IgG antibody responses and serum bactericidal titres in children following vaccination with a meningococcal A/C polysaccharide vaccine
John Paul
FEMS Immunology & Medical Microbiology, 2000
View PDFchevron_right
Age-Related Immunity to Meningococcal Serogroup C Vaccination: An Increase in the Persistence of IgG2 Correlates with a Decrease in the Avidity of IgG
Elisabeth Sanders
PLoS ONE, 2011
View PDFchevron_right
Immune Responses against Major Outer Membrane Antigens of Neisseria meningitidis in Vaccinees and Controls Who Contracted Meningococcal Disease during the Norwegian Serogroup B Protection Trial
Einar Rosenqvist
Infection and Immunity, 1998
View PDFchevron_right
Absence of Neisseria meningitidis Serogroup C-Specific Antibodies during the First Year of Life in The Netherlands: an Age Group at Risk?
Ger Rijkers , Guy Berbers
Clinical and Vaccine Immunology, 2009
View PDFchevron_right
Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children
Jeff Bezos
The Journal of Pediatrics, 1996
View PDFchevron_right
Safety and immunogenicity of a new Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in healthy adults
Joan Fusco
Vaccine, 1999
View PDFchevron_right
Kinetics of antibody responses after primary immunization with meningococcal serogroup C conjugate vaccine or secondary immunization with either conjugate or polysaccharide vaccine in adults
Guy Berbers , Ger Rijkers
Vaccine, 2009
View PDFchevron_right
Maintenance of Immune Response throughout Childhood following Serogroup C Meningococcal Conjugate Vaccination in Early Childhood
H. Findlow
Clinical and Vaccine Immunology, 2011
View PDFchevron_right
Safety and immunogenicity of three lots of meningococcal serogroup C conjugate vaccine administered at 2, 3 and 4 months of age
Stephen Lockhart
Vaccine, 2001
View PDFchevron_right
Prevalence of Serum Bactericidal Antibody to Serogroup C Neisseria meningitidis in England a Decade after Vaccine Introduction
Mary Ramsay
Clinical and Vaccine Immunology, 2012
View PDFchevron_right
Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study
Veronique Bianco , Cecilia Montalban
BMC Infectious Diseases, 2013
View PDFchevron_right
Evidence for Rise in Meningococcal Serogroup C Bactericidal Antibody Titers in the Absence of Booster Vaccination in Previously Vaccinated Children
Mohamed Tashani
The Pediatric infectious disease journal, 2017
View PDFchevron_right
Safety, Reactogenicity, and Immunogenicity of a Tetravalent Meningococcal Polysaccharide–Diphtheria Toxoid Conjugate Vaccine Given to Healthy Adults
Jacek Wysocki
The Journal of Infectious Diseases, 2002
View PDFchevron_right
Immunogenicity, Reactogenicity, and Safety of a P1.7b,4 Strain-Specific Serogroup B Meningococcal Vaccine Given to Preteens
Joanna Stewart , Ingeborg Aaberge
Clinical and Vaccine Immunology, 2007
View PDFchevron_right
Effect of Vaccination with Carrier Protein on Response to Meningococcal C Conjugate Vaccines and Value of Different Immunoassays as Predictors of Protection
Carol Thornton
Infection and Immunity, 2002
View PDFchevron_right
Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study
Mark Alderson
The Lancet. Infectious diseases, 2018
View PDFchevron_right
Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd Immunity
Ana Belen Ibarz Pavon
The Journal of …, 2008
View PDFchevron_right
Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: Interim analysis
Otto Vanderkooi
Vaccine, 2012
View PDFchevron_right
A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2–10 years
Veronique Bianco
Human Vaccines & Immunotherapeutics, 2012
View PDFchevron_right
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
Mary Ramsay
The Lancet, 2004
View PDFchevron_right